drugset / Trial / NCT04904237
Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.
NaSingle-groupOpen-labelTreatment
Summary
In this phase clinical trail, we evaluate the efficacy and feasibility of azacytidine and venetoclax as leukemia debulking treatment followed by reduced intensity conditioning regimen consisting of Fludarabine + Busulfan + Melphalan as salvage treatment in patients with refractory AML .
Timeline
- Start
- 2021-01-01
- Primary completion
- 2024-01-01
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacytidine | Other / unclassified | — | — |
| Subject | Venetoclax | Small molecule | — | — |
| Background | Busulfan | Small molecule | 6.4 mg/kg | — |
| Background | Fludarabine | Small molecule | 150 mg/m2 | — |
| Background | Melphalan | Small molecule | 70 mg/m2 | — |